{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/analgesia-mild-to-moderate-pain/management/choice-of-analgesic/","result":{"pageContext":{"chapter":{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic","depth":2,"htmlHeader":"<!-- begin field 4d5a5ddf-c325-4a52-94fb-5320e66548d3 --><h2>Scenario: Choice of analgesic</h2><!-- end field 4d5a5ddf-c325-4a52-94fb-5320e66548d3 -->","summary":"Covers the choice of analgesic for mild-to-moderate pain in children and adults.","htmlStringContent":"<!-- begin item a8920c5e-1611-4935-aa75-0619b5f1510f --><!-- begin field 7f3c8320-3cb2-461f-b1ad-acd900ad05cf --><p>From age 3 months onwards.</p><!-- end field 7f3c8320-3cb2-461f-b1ad-acd900ad05cf --><!-- end item a8920c5e-1611-4935-aa75-0619b5f1510f -->","topic":{"id":"bb91de96-92a3-5109-9e63-bfa14430451f","topicId":"c277ec09-8e05-40f0-800e-256a40ea6318","topicName":"Analgesia - mild-to-moderate pain","slug":"analgesia-mild-to-moderate-pain","lastRevised":"Last revised in August 2020","chapters":[{"id":"5ad4aa62-330c-58ef-be3d-541eb0757bd1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f5da487f-1d70-5390-8b2c-eb8ac55dcca3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"799ae015-7ff2-5d0f-adc6-2b88d19ac732","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d1128e99-9465-5c81-aa62-b5dfbd77231a","slug":"changes","fullItemName":"Changes"},{"id":"74a19ac7-0b43-56ee-9957-80e1aee10f72","slug":"update","fullItemName":"Update"}]},{"id":"2ec6ad9e-fe4e-5338-be0a-025956dceeda","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b5e613c3-899b-5b4e-8648-ff702aef6111","slug":"goals","fullItemName":"Goals"},{"id":"8fb7a002-3c19-5ab7-9ddf-8376dd8f563b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"12cf7805-8394-59b8-9dc6-25f55b2baece","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6816edfb-26c1-526d-8e15-0e9c45a99339","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"19cfc3fb-520c-5889-9816-9a767e365a43","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"85fbc6d5-aea7-52dd-8e2b-7792809cf582","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"75f84317-2f35-533b-a07b-8de3c3e62947","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0728ca52-ba22-539a-b403-09fa11cd8022","slug":"definition","fullItemName":"Definition"},{"id":"732f85cd-41d9-5528-96c3-6f242e3f8736","slug":"types-of-analgesics","fullItemName":"Types of analgesics"},{"id":"4cc4aec7-c1bc-587e-8e30-2bd567709a43","slug":"mode-of-action","fullItemName":"Mode of action"}]},{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","fullItemName":"Management","slug":"management","subChapters":[{"id":"2d9072b9-4eca-5f7a-9016-80d79ab0bd7d","slug":"choice-of-analgesic","fullItemName":"Scenario: Choice of analgesic"},{"id":"7088bd75-8950-5c20-845e-a5d6297eed85","slug":"paracetamol","fullItemName":"Scenario: Paracetamol"},{"id":"b32885df-ba75-5a6e-9fd1-cb1b6c9ee730","slug":"nsaids","fullItemName":"Scenario: NSAIDs"},{"id":"4e42679f-766d-53a7-bf28-4ec3703913a8","slug":"aspirin","fullItemName":"Scenario: Aspirin"},{"id":"cde4894f-b757-565e-ba2c-44513235cd40","slug":"weak-opioids","fullItemName":"Scenario: Weak opioids"}]},{"id":"d9fe8003-4836-534b-a8e5-d706bd32213c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"dcff9956-cb3d-54cf-b249-d2c1cdaa2596","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bce5b7d5-7da6-573e-b8a8-fddc2c7e96b6","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a15bfc66-55aa-561e-ae5e-8fea7ee56982","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"13a5c6cf-ff3c-5c3d-98fd-5f14e4ee6e2a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"66abd73d-e881-52a3-8a3a-46e9f9dea2ff","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"73f91468-8f42-546a-86e1-078847155ad0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a93d2597-ba76-5709-9989-de6b10c60c42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3072fb03-9470-5fa4-a035-2669e98df9d8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"63754c66-5c6d-5b5b-8baa-5426c48af691","slug":"age-younger-than-16-years","fullItemName":"Age younger than 16 years","depth":3,"htmlHeader":"<!-- begin field 4b43cee8-8612-4b6a-9142-35f08c27423a --><h3>Which analgesic should I prescribe for children aged under 16 years?</h3><!-- end field 4b43cee8-8612-4b6a-9142-35f08c27423a -->","summary":null,"htmlStringContent":"<!-- begin item 13e3d845-21f2-43d6-9a4f-d480f01d01e1 --><!-- begin field baee7a2f-bb76-4bcc-8357-14387426e1ba --><ul><li><strong>Prescribe either paracetamol or ibuprofen alone.</strong><ul><li>If the child does not respond to the first-line analgesic, check their adherence and that an appropriate dose is being taken. If adherence and dose are appropriate, switch analgesic:<ul><li>If <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> has been used, switch to ibuprofen alone. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a> for prescribing information on NSAIDs.</li><li>If ibuprofen has been used, switch to <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> alone.</li></ul></li><li>If the child does not respond sufficiently to appropriate doses of either drug alone, consider alternating <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> and ibuprofen.<ul><li>Add a dose of the second drug (for example 2–3 hours after the first drug) provided that the parents/carers are confident to do this.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">Paracetamol</a> is usually given every 6 hours and ibuprofen every 8 hours. Care needs to be taken not to exceed the maximum dose of each drug in a 24-hour period.</li><li>A treatment diary may be useful if the parents/carers find it difficult to remember which was the last drug given and at what time.</li><li>If the child is still in pain or more than short courses of analgesics are required, consider seeking specialist advice. </li></ul></li><li>Treat the underlying cause of the pain whenever possible.</li></ul></li><li><strong>The following treatment options are not recommended for children in primary care:</strong><ul><li>Use of paracetamol and ibuprofen at the same time.</li><li>Naproxen.</li><li>Diclofenac.</li><li>Aspirin.</li><li>Weak opioids (codeine, dihydrocodeine, and tramadol).</li></ul></li></ul><!-- end field baee7a2f-bb76-4bcc-8357-14387426e1ba --><!-- end item 13e3d845-21f2-43d6-9a4f-d480f01d01e1 -->","subChapters":[{"id":"946ff180-acc5-5d5c-a05b-9b9f40372a46","slug":"basis-for-recommendation-a7e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2f4c849a-d81f-4b1e-8706-77bf14b28de8 --><h4>Basis for recommendation</h4><!-- end field 2f4c849a-d81f-4b1e-8706-77bf14b28de8 -->","summary":null,"htmlStringContent":"<!-- begin item a7ebd01c-6391-458f-91d5-b148cfd8d1cc --><!-- begin field 00e94904-97dd-4674-877a-88f114474d5c --><h5>Choice of analgesic</h5><ul><li>The recommendation to use either paracetamol alone or ibuprofen alone first line has been extrapolated from the National Institute for Health and Care Excellence (NICE) guideline <em>Fever in under 5s: assessment and initial management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">National Collaborating Centre for Women's and Children's Health, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">NICE, 2019</a>].</li><li>The recommendation to consider alternating doses of paracetamol and ibuprofen if the child does not respond sufficiently to appropriate doses of either drug alone is based on the expert opinion of the NICE Guideline Development Group (GDG) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">National Collaborating Centre for Women's and Children's Health, 2013</a>].<ul><li>The GDG considered it not unreasonable to alternate ibuprofen and paracetamol if standalone treatment has not been successful after considering evidence from three randomized controlled trials (RCTs) comparing paracetamol alone with paracetamol and ibuprofen alternating, and seven RCTs comparing ibuprofen alone with paracetamol and ibuprofen alternating.</li><li>The GDG found limited evidence of a greater improvement in quality of life and temperature reduction when ibuprofen was alternated with paracetamol than when either drug was given alone, but commented on the lack of safety data for this regimen.</li></ul></li></ul><h5>Treatments not recommended in primary care</h5><ul><li>Paracetamol plus ibuprofen is not recommended because of the theoretical increased risk of overdose and renal toxicity, although there is no pharmacokinetic interaction between both drugs. NICE recommends that paracetamol and ibuprofen should not be administered at the same time to children with fever because taking both drugs together is more complicated and the risk of unintentionally exceeding the maximum recommended dose may be increased compared with using either drug on its own [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">National Collaborating Centre for Women's and Children's Health, 2013</a>]. </li><li>Naproxen is only licensed for use in children with juvenile rheumatoid arthritis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2019a</a>].</li><li>Diclofenac solid dose forms containing more than 25 mg of diclofenac are not licensed for use in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">Joint Formulary Committee, 2020</a>]. Diclofenac 25 mg tabs are licensed for [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2019b</a>]:<ul><li>Children aged 1–12 years for treatment of juvenile chronic arthritis.</li><li>Children aged 9 years and over for short-term treatment of fever related to infections of the ear, nose, or throat (for example pharyngotonsillitis and otitis media), and as monotherapy or as adjunct therapy with morphine or other opiates (due to its opiate-sparing effect) for the relief of acute post-operative pain.</li></ul></li><li>Aspirin is not licensed for use in children aged younger than 16 years because of the risk of Reye's syndrome (a very rare but often fatal disease characterized by encephalopathy and fatty degeneration of the liver) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">CSM, 2002</a>].</li><li>Tramadol and dihydrocodeine tablets are licensed for use in children aged over 12 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020b</a>]. However, CKS recommends seeking specialist advice if a weak opioid is being considered to treat mild-to-moderate pain in a child aged younger than 16 years.</li><li>Codeine is contraindicated in children aged under 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">ABPI, 2020c</a>]. <ul><li>Following a review by the European Medicines Agency (EMA), the use of codeine as an analgesic for children and adolescents is now restricted [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">EMA, 2013</a>].</li><li>The EMA has advised that it should only be used to relieve acute moderate pain in children aged over 12 years if pain cannot be relieved by other analgesics, such as paracetamol or ibuprofen.</li></ul></li></ul><!-- end field 00e94904-97dd-4674-877a-88f114474d5c --><!-- end item a7ebd01c-6391-458f-91d5-b148cfd8d1cc -->","subChapters":[]}]},{"id":"d059d690-635a-54ff-9890-9a35bb2b2c10","slug":"age-16-years-older","fullItemName":"Age 16 years and older","depth":3,"htmlHeader":"<!-- begin field 9365795b-e003-4912-b422-48df96081698 --><h3>Which analgesic should I prescribe for adults and children aged 16 years and older?</h3><!-- end field 9365795b-e003-4912-b422-48df96081698 -->","summary":null,"htmlStringContent":"<!-- begin item 00c203d2-cc9a-4081-92c9-fbc0c2e45e5d --><!-- begin field c8cc5dc1-6b11-4133-8d79-41ef33b5a451 --><ul><li><strong>In adults and children aged 16 years and older, </strong>a stepwise strategy for managing mild-to-moderate pain is recommended: <ul><li><strong>Step 1</strong> — start <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a>. </li><li><strong>Step 2</strong> — substitute the <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> with ibuprofen. If the person is unable to take a <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/nsaids/\">nonsteroidal anti-inflammatory drug</a> (NSAID), use a <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/\">weak opioid</a> (such as codeine phosphate).</li><li><strong>Step 3 </strong>— add <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> to the ibuprofen or <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/\">weak opioid</a>.</li><li><strong>Step 4 </strong>— continue with <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> and replace the ibuprofen with an alternative NSAID (such as naproxen).</li><li><strong>Step 5</strong> — add a <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/\">weak opioid</a> to the <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/paracetamol/\">paracetamol</a> and/or NSAID.</li></ul></li><li><strong>When prescribing analgesics:</strong><ul><li>Ensure a full therapeutic dose of one analgesic is used before switching to (or combining with) another analgesic.</li><li>Treat the underlying cause of the pain whenever possible.</li><li>Ensure that people who experience continuous pain receive regular analgesia following a full clinical assessment.</li><li>Avoid combination analgesics as first-line treatment. <ul><li>Prescribing single-constituent analgesics to allow independent titration of each drug, taking into account local prescribing guidelines.</li><li>Consider fixed-dose combination analgesics (except those with low-doses of opioids) for people with chronic, stable pain and for people taking a lot of tablets (to reduce the number of tablets taken). </li><li>Be aware that fixed-dose combination analgesics containing low doses of opioids (such as codeine 8 mg plus paracetamol 500 mg or dihydrocodeine 10 mg plus paracetamol 500 mg) are no more effective than paracetamol alone and can cause opioid <a class=\"topic-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/management/weak-opioids/#adverse-effects\">adverse effects</a>, such as constipation.</li></ul></li></ul></li></ul><!-- end field c8cc5dc1-6b11-4133-8d79-41ef33b5a451 --><!-- end item 00c203d2-cc9a-4081-92c9-fbc0c2e45e5d -->","subChapters":[{"id":"16930be3-6941-531d-904b-cb6259cb351c","slug":"basis-for-recommendation-7c0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5c90100a-0eb8-4571-9127-c7da4a6634e8 --><h4>Basis for recommendation</h4><!-- end field 5c90100a-0eb8-4571-9127-c7da4a6634e8 -->","summary":null,"htmlStringContent":"<!-- begin item 7c037afd-e84c-4e88-a2ef-8f2ab9e51ef4 --><!-- begin field 4fbb01b7-7e2a-4dbf-b86f-4999fecc51bf --><h5>Stepwise strategy for managing mild-to-moderate pain</h5><ul><li>The stepwise treatment strategy is based on the <a data-hyperlink-id=\"a083e7b3-c775-41c4-9d4e-ac120143961b\" href=\"https://www.who.int/cancer/palliative/painladder/en/\">WHO pain ladder</a> developed by the World Health Organization (WHO) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">WHO, 2010</a>], and the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of chronic pain: a national clinical guideline</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">SIGN, 2013</a>].<ul><li>The WHO pain ladder was developed and validated only for the treatment of cancer pain, but it is widely used to guide basic treatment of acute and chronic pain. Although there is little evidence to support its use in chronic pain, it provides an analgesic strategy for non-specialists [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">SIGN, 2013</a>].</li></ul></li></ul><h5>Combining analgesics</h5><ul><li>The recommendations on combining analgesics are based on expert opinion in <em>Advice from the CSM Expert Working Group on analgesic options in treatment of mild-to-moderate pain</em> published by the British Pain Society and the Medicines and Healthcare products Regulatory Agency (MHRA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">MHRA, 2004</a>] and in a MeReC bulletin published by the National Prescribing Centre [<a class=\"bibliography-reference internal-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/references/\">MeReC, 2006</a>].</li></ul><!-- end field 4fbb01b7-7e2a-4dbf-b86f-4999fecc51bf --><!-- end item 7c037afd-e84c-4e88-a2ef-8f2ab9e51ef4 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}